Interpace Diagnostics Group (NASDAQ:IDXG) has expanded the application of its pathology test PancraGEN beyond its use to see whether pancreatic cysts are cancerous to include bile duct strictures and solid pancreatic lesions.
PancraGEN is a DNA-based molecular pathology test that assesses the risk of cancer in pancreatic cysts.
The widening of PancraGEN's application to include the detection of cancer in solid pancreatic and bile duct lesions is based on new guidelines that have come out, as well as a raft of recent clinical studies.
Indeed, the most recent National Comprehensive Cancer Network guidelines for Hepatobiliary cancers recommend molecular testing in patients who are suffering from bile duct obstruction or other abnormalities in order to diagnose bile duct cancer. The American College of Gastroenterology guidelines for the management of the management of primary sclerosing cholangitis, a chronic liver disease, also suggest the introduction of molecular testing to exclude a diagnosis of bile duct cancer.
Three new peer-reviewed papers written about research conducted at Columbia University, Washington University and the Arizona Center for Digestive Health support the use of PancraGEN for detecting cancer in bile duct strictures and solid pancreatic lesions as well.
“We are pleased to see the updated NCCN guidelines and the multiple peer-reviewed papers that further support the use of molecular diagnostics in assessing the potential for pancreatic and bile duct cancers across a more expansive patient population,” said Jack Stover, CEO of Interpace, in a statement.
PancraGEN is 90% accurate according to clinical studies. Pancreatic cancer is difficult to diagnose in early stages and spreads rapidly, with symptoms surfacing when the cancer is advanced.
Interpace's shares were flat in afternoon trade at US$1.02.